Lb Pharmaceuticals (LBRX) Accounts Payables (2024 - 2026)

Lb Pharmaceuticals has reported Accounts Payables for 3 years, with the latest figure at $7.1 million in Q1 2026.

• For the quarter ending Q1 2026, Accounts Payables changed N/A year-over-year to $7.1 million; the trailing twelve-month figure through Mar 2026 stood at $7.1 million (changed N/A YoY), and the FY2025 full-year result was $2.1 million, down 8.32% from the prior year.
• Accounts Payables for Q1 2026 stood at $7.1 million, up from $2.1 million in the prior quarter.
• The five-year high for Accounts Payables was $7.1 million in Q1 2026, with the low at $2.1 million in Q4 2025.
• Average Accounts Payables over 3 years is $3.5 million, with a median of $2.5 million recorded in 2024.
• Peak annual rise in Accounts Payables reached 8.32% in 2025, while the deepest fall reached 8.32% in 2025.
• Tracing LBRX's Accounts Payables over 3 years: stood at $2.3 million in 2024, then retreated by 8.32% to $2.1 million in 2025, then soared by 234.7% to $7.1 million in 2026.
• The last three Accounts Payables figures came in at $7.1 million (Q1 2026), $2.1 million (Q4 2025), and $2.6 million (Q3 2025), per Business Quant data.

Peer Comparison